Botox maker Allergan confirmed Thursday that it was in early talks to combine with drug giant Pfizer Inc. in a deal that, if completed, would cap a remarkable spree of mergers this year that’s roiling the healthcare industry.
Allergan, a Dublin, Ireland-based firm with sizable operations in Irvine, said in a statement that it was approached by Pfizer and the discussions were “friendly,” but cautioned there was “no certainty” the talks would lead to a merger.
Allergan also declined comment on any possible terms of a deal. Allergan had a total stock-market value of $113 billion as of Wednesday’s close, so a Pfizer acquisition likelywould have a price tag well above that figure.
That would be the biggest deal of a year in which companies throughout the healthcare industry have joined forces to reposition themselves as various market and government forces, notably the Affordable Care Act, have changed the growth outlook for the firms’ revenues and profits.
Full content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI